ContractTermination and Asset Transfer Agreement • May 5th, 2020 • New York
EX-10.2 3 a123114ex102.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION VERSION STRICTLY CONFIDENTIAL TERMINATION AND ASSET TRANSFER AGREEMENT by and between NOVARTIS PHARMA AG, NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. and ARRAY BIOPHARMA INC. Dated as of November 26, 2014 [***] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information. TABLE OF CONTENTS
TERMINATION AND ASSET TRANSFER AGREEMENTTermination and Asset Transfer Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO THE TERMINATION AND ASSET TRANSFER AGREEMENT (this “Amendment”) is entered into as of January 19, 2015 (the “Amendment Date”) by and between Novartis Pharma AG, a Swiss corporation (“Novartis”); Novartis International Pharmaceutical Ltd., a corporation organized and existing under the laws of Bermuda, for purposes of Article II, Section 4.1, Section 5.1(d) and Article X only of the Agreement (as defined below) (“NIP”); and Array BioPharma Inc., a Delaware corporation (“Array”).
